A5062560275- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Gastric Cancer Management and Outcomes
- HER2/EGFR in Cancer Research
- Sarcoma Diagnosis and Treatment
- Colorectal Cancer Surgical Treatments
- Breast Cancer Treatment Studies
- Autoimmune Bullous Skin Diseases
- Cardiac tumors and thrombi
- Multiple Myeloma Research and Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
- Platelet Disorders and Treatments
- Burn Injury Management and Outcomes
- Urinary and Genital Oncology Studies
- Uterine Myomas and Treatments
- Musculoskeletal synovial abnormalities and treatments
- Estrogen and related hormone effects
- Tissue Engineering and Regenerative Medicine
- Connective Tissue Growth Factor Research
- Peptidase Inhibition and Analysis
- Cancer Diagnosis and Treatment
- Endometrial and Cervical Cancer Treatments
- Colorectal Cancer Treatments and Studies
- Pituitary Gland Disorders and Treatments
- Systemic Lupus Erythematosus Research
Bilkent University
2025
Ankara Bilkent City Hospital
2023-2025
Memorial Ankara Hospital
2023-2025
City Hospital
2023
Ankara Mevki Asker Hastanesi
2023
Süleyman Demirel University
2014
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but are associated with immune-related adverse events (irAEs). Pembrolizumab, an anti-PD-1 antibody, is widely used in non-small cell lung (NSCLC), yet immune thrombocytopenia remains a rare potentially fatal complication. We report case of 55-year-old male metastatic NSCLC who developed pembrolizumab-associated thrombocytopenia. The patient initially responded well to combination therapy pembrolizumab, carboplatin, and...
Introduction: Biliary tract cancers (BTC) comprise a heterogeneous group of malignancies, including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The main determinants prognosis in BTC are the stage disease eligibility for curative treatment. Additionally, liver functional capacity is also one factors influencing survival biliary cancers. age–bilirubin–INR–creatinine (ABIC) score has been previously shown to predict hepatic diseases. aim our study...
Introduction: Locoregional gastric cancer is a still serious problem and perioperative treatments may improve the success of management. Different regimens were examined. The present study purposed to compare efficacy fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) docetaxel-cisplatin-fluorouracil (DCF) regimens. Methods: A retrospective multicenter assessed patients with locoregional cancer. There are 240 (137 DCF, 103 FLOT). Survival rates compared. Results: Demographic features...
Introduction Letrozole is an aromatase inhibitor (AI), which suppresses plasma estrogen levels by inhibiting the enzyme, that causes conversion of androgens to in peripheral tissues. There very few information literature regarding development acute heart failure after AI use. We would like report a case patient who was started letrozole for hormonal treatment and developed due this. Case Fifty-seven-year-old woman with hormone positive breast cancer operated neoadjuvant chemotherapy received...
Introduction . In this study, we aimed to investigate the effects of pre-treatment clinical and laboratory characteristics on prognosis in ovarian cancer patients diagnosed our clinic. all patients, surgery was not possible, they were qualified for neoadjuvant treatment. Material methods. Records 96 with carcinoma, who eligible at time diagnosis treatment, reviewed retrospectively. Results. For OS, analyzed age (p = 0.106), ECOG 0.007), menstrual status 0.211), FIGO stage 0.314), origin...
ABS TRACT Objective: Synovial sarcoma, an aggressive subtype of soft tissue tumors, mainly occurs in young individuals.In patients with synovial the tumor is predominantly localized lower extremities, cases.The present study aimed to investigate contribution localization prognosis sarcoma and determine factors affecting patient survival.Material Methods: We retrospectively analyzed clinical data 35 who were treated at our clinic between February 2000 October 2022.Overall survival (OS)...
While some clinics have adopted abbreviated neoadjuvant treatment for HER2-positive breast cancer, there remains a shortage of comprehensive clinical data to support this practice. This is retrospective, multicenter study. A total 142 patients were included in the study who are aged ≤ 65 years, with left ventricular ejection fraction ≥ 50%, received chemotherapy and underwent surgery at 10 different oncology centers Türkiye between October 2016 December 2022. The arms divided into 4-6 cycles...
Introduction: Endometrium cancer is the most common gynaecological malignancy in developed countries. In this study, we aimed to investigate effect of HER2 positivity on prognosis endometrial cancer. Methods: our patients admitted clinic with a diagnosis between September 2019 and December 2023 were retrospectively evaluated. Human epidermal growth factor receptor 2 (HER2) immunohistochemistry was performed 121 patients. HER2-low group (HER2 score: 0 1) HER2-high 3) defined according score...
We aimed to compare FOLFIRI and bevacizumab with aflibercept in terms of overall survival (OS), progression-free (PFS) safety patients RAS-mutant metastatic colon cancer who progressed after first-line FOLFOX or XELOX treatment. This retrospective study included 243 from 15 different centres Turkey. The endpoints the were OS, PFS side effect outcomes. median age was 60 (21–85) years. Of enrolled study, 114 (46.9%) received 129 (53.1%) bevacizumab. Median OS 11.2 (95% CI: 9.1–13.2) months...
Hepatotoxicity is observed due to cyclin-dependent kinase (CDK4/6) inhibitors used treat hormone receptor-positive metastatic breast cancer. However, it should not be ignored that denosumab may hepatotoxic, although rare.A 73-year-old female patient with cancer axillary lymph node, adrenal gland and bone metastases was started on ribociclib letrozole treatment. Ribociclib treatment discontinued grade 4 hepatotoxicity during treatment, but liver function tests did decrease. After...
Introduction Cabozantinib is a multikinase inhibitor agent used in the treatment of hepatocellular, renal, and thyroid cancers. The development heart failure after cabozantinib initiation an extremely rare side effect, with only four case reports published literature. We describe cabozantinib-induced cardiac patient cancer refractory to standard treatment. Case report Fifty-seven-year-old woman had no history cardiovascular disease. Echocardiography prior chemotherapy revealed normal...
Objective: The aim of our study is to show the efficacy and side effects tofacitinib in patients with rheumatoid arthritis (RA). Methods: 66 Patients who were followed up rheumatology outpatient clinic, older than 18 years, used for at least three months included. Blood count, liver transaminase levels, cholesterol triglyceride C-reactive protein (CRP) erythrocyte sedimentation rate (ESR) determined before third sixth treatment. Before after treatment, DAS 28-ESR, morning stiffness duration,...
Abstract Introduction: Human epidermal growth factor receptor 2 (HER2) overexpression is a characteristic observed in 18%–20% of all breast cancer cases. While some clinics have adopted abbreviated neoadjuvant treatment for HER2-positive cancer, there remains shortage comprehensive clinical data to support this practice. One the primary considerations need regimens that minimize cardiac toxicity while not compromising survival outcomes. This issue continues be topic discussion within medical...
Abstract Background Bladder cancer surgery is critical for treatment, and systemic treatment before or after cystectomy may be necessary. We aimed to investigate the efficacy response neoadjuvant adjuvant treatments. Methods Data on 93 patients with resectable muscle-invasive bladder were analyzed retrospectively. Patients who received chemotherapies included. The group was divided into pathological responders non-responders. Overall survival disease-free calculated. Results median age 61.5...